ZEALAND PHARMA A/S (22Z.DE) Fundamental Analysis & Valuation

FRA:22Z • DK0060257814

Current stock price

38.3 EUR
+0.98 (+2.63%)
Last:

This 22Z.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. 22Z.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 22Z was profitable.
  • In the past year 22Z had a positive cash flow from operations.
  • In the past 5 years 22Z reported 4 times negative net income.
  • In the past 5 years 22Z reported 4 times negative operating cash flow.
22Z.DE Yearly Net Income VS EBIT VS OCF VS FCF22Z.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

1.2 Ratios

  • The Return On Assets of 22Z (40.47%) is better than 97.47% of its industry peers.
  • The Return On Equity of 22Z (43.52%) is better than 97.47% of its industry peers.
  • 22Z has a Return On Invested Capital of 32.06%. This is amongst the best in the industry. 22Z outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 40.47%
ROE 43.52%
ROIC 32.06%
ROA(3y)-2.14%
ROA(5y)-26.75%
ROE(3y)-4.39%
ROE(5y)-54.05%
ROIC(3y)N/A
ROIC(5y)N/A
22Z.DE Yearly ROA, ROE, ROIC22Z.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

1.3 Margins

  • The Profit Margin of 22Z (70.05%) is better than 96.20% of its industry peers.
  • 22Z has a better Operating Margin (75.52%) than 98.73% of its industry peers.
  • 22Z has a better Gross Margin (99.99%) than 97.47% of its industry peers.
  • In the last couple of years the Gross Margin of 22Z has remained more or less at the same level.
Industry RankSector Rank
OM 75.52%
PM (TTM) 70.05%
GM 99.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y0%
22Z.DE Yearly Profit, Operating, Gross Margins22Z.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. 22Z.DE Health Analysis

2.1 Basic Checks

  • 22Z has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • 22Z has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 22Z has more shares outstanding
  • Compared to 1 year ago, 22Z has an improved debt to assets ratio.
22Z.DE Yearly Shares Outstanding22Z.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
22Z.DE Yearly Total Debt VS Total Assets22Z.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • 22Z has an Altman-Z score of 10.23. This indicates that 22Z is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 10.23, 22Z belongs to the top of the industry, outperforming 86.08% of the companies in the same industry.
  • The Debt to FCF ratio of 22Z is 0.06, which is an excellent value as it means it would take 22Z, only 0.06 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.06, 22Z belongs to the top of the industry, outperforming 98.73% of the companies in the same industry.
  • 22Z has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • 22Z has a better Debt to Equity ratio (0.03) than 78.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.06
Altman-Z 10.23
ROIC/WACC4.81
WACC6.66%
22Z.DE Yearly LT Debt VS Equity VS FCF22Z.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • 22Z has a Current Ratio of 23.57. This indicates that 22Z is financially healthy and has no problem in meeting its short term obligations.
  • 22Z has a Current ratio of 23.57. This is amongst the best in the industry. 22Z outperforms 100.00% of its industry peers.
  • 22Z has a Quick Ratio of 23.57. This indicates that 22Z is financially healthy and has no problem in meeting its short term obligations.
  • 22Z has a better Quick ratio (23.57) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 23.57
Quick Ratio 23.57
22Z.DE Yearly Current Assets VS Current Liabilites22Z.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 22Z.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 690.04% over the past year.
  • Looking at the last year, 22Z shows a very strong growth in Revenue. The Revenue has grown by 14598.86%.
  • Measured over the past years, 22Z shows a very strong growth in Revenue. The Revenue has been growing by 116.89% on average per year.
EPS 1Y (TTM)690.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.06%
Revenue 1Y (TTM)14598.86%
Revenue growth 3Y345.83%
Revenue growth 5Y116.89%
Sales Q2Q%662.48%

3.2 Future

  • The Earnings Per Share is expected to decrease by -53.85% on average over the next years. This is quite bad
  • Based on estimates for the next years, 22Z will show a very negative growth in Revenue. The Revenue will decrease by -24.16% on average per year.
EPS Next Y-89.93%
EPS Next 2Y-44.69%
EPS Next 3Y-33.05%
EPS Next 5Y-53.85%
Revenue Next Year-48.95%
Revenue Next 2Y-35.24%
Revenue Next 3Y-53.14%
Revenue Next 5Y-24.16%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
22Z.DE Yearly Revenue VS Estimates22Z.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
22Z.DE Yearly EPS VS Estimates22Z.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 20 -20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

5

4. 22Z.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 2.98, which indicates a rather cheap valuation of 22Z.
  • 97.47% of the companies in the same industry are more expensive than 22Z, based on the Price/Earnings ratio.
  • 22Z's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.23.
  • 22Z is valuated quite expensively with a Price/Forward Earnings ratio of 29.59.
  • 77.22% of the companies in the same industry are more expensive than 22Z, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.42, 22Z is valued a bit more expensive.
Industry RankSector Rank
PE 2.98
Fwd PE 29.59
22Z.DE Price Earnings VS Forward Price Earnings22Z.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, 22Z is valued cheaply inside the industry as 97.47% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2.04
EV/EBITDA -1.72
22Z.DE Per share data22Z.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • 22Z has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as 22Z's earnings are expected to decrease with -33.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-44.69%
EPS Next 3Y-33.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 22Z.DE Dividend Analysis

5.1 Amount

  • 22Z does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

22Z.DE Fundamentals: All Metrics, Ratios and Statistics

ZEALAND PHARMA A/S

FRA:22Z (3/20/2026, 7:00:00 PM)

38.3

+0.98 (+2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)05-07
Inst Owners47.87%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap1.77B
Revenue(TTM)9.21B
Net Income(TTM)6.46B
Analysts81.67
Price Target94.3 (146.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.5%
Min EPS beat(2)30.39%
Max EPS beat(2)86.6%
EPS beat(4)2
Avg EPS beat(4)-127.91%
Min EPS beat(4)-623.11%
Max EPS beat(4)86.6%
EPS beat(8)4
Avg EPS beat(8)-61.66%
EPS beat(12)6
Avg EPS beat(12)-30.6%
EPS beat(16)8
Avg EPS beat(16)-22.5%
Revenue beat(2)1
Avg Revenue beat(2)0.21%
Min Revenue beat(2)-45.16%
Max Revenue beat(2)45.58%
Revenue beat(4)1
Avg Revenue beat(4)-19.43%
Min Revenue beat(4)-74.61%
Max Revenue beat(4)45.58%
Revenue beat(8)3
Avg Revenue beat(8)-1.19%
Revenue beat(12)6
Avg Revenue beat(12)49.37%
Revenue beat(16)7
Avg Revenue beat(16)34.17%
PT rev (1m)-2.04%
PT rev (3m)-7.48%
EPS NQ rev (1m)-4.62%
EPS NQ rev (3m)-4.62%
EPS NY rev (1m)-37.2%
EPS NY rev (3m)-48.37%
Revenue NQ rev (1m)255.43%
Revenue NQ rev (3m)255.43%
Revenue NY rev (1m)-7.31%
Revenue NY rev (3m)-5.94%
Valuation
Industry RankSector Rank
PE 2.98
Fwd PE 29.59
P/S 1.43
P/FCF 2.04
P/OCF 2.02
P/B 0.89
P/tB 0.89
EV/EBITDA -1.72
EPS(TTM)12.85
EY33.55%
EPS(NY)1.29
Fwd EY3.38%
FCF(TTM)18.76
FCFY48.97%
OCF(TTM)18.96
OCFY49.5%
SpS26.74
BVpS43.04
TBVpS42.91
PEG (NY)N/A
PEG (5Y)N/A
Graham Number111.55
Profitability
Industry RankSector Rank
ROA 40.47%
ROE 43.52%
ROCE 45.53%
ROIC 32.06%
ROICexc 2799.28%
ROICexgc 3767.06%
OM 75.52%
PM (TTM) 70.05%
GM 99.99%
FCFM 70.14%
ROA(3y)-2.14%
ROA(5y)-26.75%
ROE(3y)-4.39%
ROE(5y)-54.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y0%
F-Score9
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.06
Debt/EBITDA 0.05
Cap/Depr 252.35%
Cap/Sales 0.75%
Interest Coverage 311.61
Cash Conversion 93.49%
Profit Quality 100.12%
Current Ratio 23.57
Quick Ratio 23.57
Altman-Z 10.23
F-Score9
WACC6.66%
ROIC/WACC4.81
Cap/Depr(3y)132.63%
Cap/Depr(5y)92.56%
Cap/Sales(3y)9.55%
Cap/Sales(5y)12.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)690.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.06%
EPS Next Y-89.93%
EPS Next 2Y-44.69%
EPS Next 3Y-33.05%
EPS Next 5Y-53.85%
Revenue 1Y (TTM)14598.86%
Revenue growth 3Y345.83%
Revenue growth 5Y116.89%
Sales Q2Q%662.48%
Revenue Next Year-48.95%
Revenue Next 2Y-35.24%
Revenue Next 3Y-53.14%
Revenue Next 5Y-24.16%
EBIT growth 1Y647.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.2%
EBIT Next 3Y-30.81%
EBIT Next 5Y-15.06%
FCF growth 1Y784.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y801.74%
OCF growth 3YN/A
OCF growth 5YN/A

ZEALAND PHARMA A/S / 22Z.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ZEALAND PHARMA A/S (22Z.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE.


What is the valuation status for 22Z stock?

ChartMill assigns a valuation rating of 5 / 10 to ZEALAND PHARMA A/S (22Z.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for ZEALAND PHARMA A/S?

ZEALAND PHARMA A/S (22Z.DE) has a profitability rating of 6 / 10.


How financially healthy is ZEALAND PHARMA A/S?

The financial health rating of ZEALAND PHARMA A/S (22Z.DE) is 9 / 10.


Can you provide the expected EPS growth for 22Z stock?

The Earnings per Share (EPS) of ZEALAND PHARMA A/S (22Z.DE) is expected to decline by -89.93% in the next year.